|
A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache Clinical research trials and A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache. A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache clinical trial. Test subjects typically obtain the finest healthcare available for their A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache  A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache
A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache
For Condition: Migraine Headache
Status: Completed
Sponsor(s): Elan Pharmaceuticals ,
Synopsis: The purpose of this study is to determine if zonisamide is effective as a preventative medication for individuals with migraine headache.
Details: The pharmacologic treatment of migraine may be acute (abortive, symptomatic) or preventive (prophylactic). Preventive medication is usually given daily for months or years; however, treatment may also be given in an intermittent regimen. Most migraine prophylactic medications were designed to treat other disorders, and they can be divided into three groups: 1) Serotonergic or monoaminergic agents such as methysergide, which have demonstrated high degrees of effectiveness; 2) Non-serotonergic drugs such as beta-blockers, tricyclic antidepressants, valproate; and 3) Drugs with lesser demonstrated effectiveness, such as selective serotonin reuptake inhibitors, calcium channel antagonists, and non-steroidal anti-inflammatory drugs. The choice of treatment must be individualized, and is influenced by contraindications, potential side effects, the need to treat associated symptoms like tension-type headache and insomnia, and drug cost. Anticonvulsants, such as valproate, have shown significant degrees of efficacy in migraine prophylaxis when used in low doses. Considering the differences in proposed mechanisms of action of these agents, it is likely that a novel anticonvulsant such as zonisamide may also be an effective prophylactic treatment for migraine.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: INCLUSION: Subjects who meet all the following criteria will be eligible to participate in the study: - Are men or women, between the ages of 18 and 65, inclusive. - Satisfy diagnostic criteria for migraine headache, consistent with criteria described in Headache Classification Criteria. - Have at least 4 migraine attacks per 28 days [each attack separated by at least 48 hours] prior to the Screening Visit and experience at least 4 migraine attacks during the Screen/Baseline Phase. - Agree to not become pregnant during the study and agree to use an adequate method of birth control during the study such as an adequate barrier method, hormonal contraceptive, or surgical sterilization. All women of childbearing potential must have a negative pregnancy test before entering the study and during the study. - Are able to swallow the capsules whole. - Are willing and able to follow Investigator instructions and study procedures, complete the daily diary, and report adverse events. EXCLUSION: Subjects meeting any of the following criteria will not be eligible to participate in this study: - Have required more than 3 different rescue medications for control of a single attack anytime within 3 months prior to the Screening Visit. - Have cluster headache or chronic tension type headache and are unable to distinguish between their different types of headache. - Have basilar or hemiplegic migraine. - Have used triptans more than 3 times per week within 3 months prior to the Screening Visit. - Have received botulinum toxin injection(s) within 3 months prior to the Screening Visit. - Have taken any other prophylactic medications for migraine within 5 half-lives prior to the Baseline Visit. - Are pregnant or lactating. - Have a history or current diagnosis of psychiatric disorder likely to require pharmacological intervention (e.g., antidepressants, MAO inhibitors, antipsychotics, mood-stabilizers, anxiolytics) during the study. - Have clinically unstable cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease. - Have laboratory test results that, in the opinion of the Investigator, are clinically significant abnormalities. - Require treatment with any medication (e.g., daily opioids, daily beta-blockers, daily non-steroidal anti-inflammatory drugs, carbonic anhydrase inhibitors, eletriptan) or herbal supplements (e.g., St. John’s Wort, ginseng, ginkgo biloba, kava kava, melatonin, petadolex) that might interact adversely with, or obscure, the action of the study medication. - Have received psychoactive medication (e.g., other anticonvulsant drugs, antidepressants, antipsychotics, anxiolytics, mood stabilizers) within 5 half-lives prior to the Baseline Visit. - Have previously enrolled in this study or previously treated with zonisamide. - Have previously failed an adequate trial of another antiepilepsy drug for the treatment of migraine. - Have a history of allergy or hypersensitivity to zonisamide or other sulfonamides. - Have a history of skin rash, without other diagnosis, associated with any medication or any medical condition. - Have a history of nephrolithiasis. - Have received an experimental drug or used an experimental device within 30 days of the Screening Visit. - Have a history of drug or alcohol abuse within 12 months prior to the Screening Visit.
Total Enrollment: 204
Location and Contact Information:
Medical Affiliated Research Center
Huntsville, Alabama, 35801
United States
Neurological Associates of Tulsa
Tulsa, Oklahoma, 74136
United States
Radiant Research
Salt Lake City, Utah, 84111
United States
Mercy Health Research
Chesterfield, Missouri, 63017
United States
The New England Center for Headache
Stamford, Connecticut, 06902
United States
MetaClin Research
Austin, Texas, 19107
United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
United States
University of South Alabama Medical Ctr Department of Neurology
Mobile, Alabama, 36693
United States
Headache Care Center
Springfield, Missouri, 65804
United States
Radiant Research
Overland Park, Kansas, 66215
United States
Houston Headache Clinic
Houston, Texas, 77004
United States
Valley Neurological Headache Clinic
Phoenix, Arizona, 85020
United States
Michigan Head-Pain & Neurological Institute
Ann Arbor, Michigan, 48104
United States
Additional Information:
Study ID Numbers: AN46046-228;
Study Start Date: March 2002
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00055484
Other Migraine Headache Studies:
1. A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache
Related Studies:
Other Migraine Headache Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects with Migraine Headache
|
|
|
|
|
|
|
|
